CalciMedica (NASDAQ:CALC) PT Raised to $20.00

CalciMedica (NASDAQ:CALC) had its target price increased by analysts at Oppenheimer from $14.00 to $20.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 323.73% from the company’s current price.

Several other equities research analysts have also recently issued reports on CALC. Singular Research raised shares of CalciMedica to a “moderate buy” rating in a research note on Friday, June 28th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of CalciMedica in a research report on Tuesday.

CalciMedica Stock Up 3.1 %

CALC opened at $4.72 on Wednesday. The company has a market cap of $50.74 million, a PE ratio of -2.20 and a beta of 1.28. CalciMedica has a twelve month low of $1.75 and a twelve month high of $8.38. The company has a 50-day moving average price of $5.08 and a 200 day moving average price of $4.68.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Monday, May 13th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07. As a group, sell-side analysts expect that CalciMedica will post -2.15 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Robert N. Wilson purchased 8,443 shares of CalciMedica stock in a transaction dated Thursday, June 27th. The shares were acquired at an average price of $3.23 per share, for a total transaction of $27,270.89. Following the acquisition, the director now directly owns 258,918 shares in the company, valued at $836,305.14. The purchase was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 53.30% of the company’s stock.

Institutional Trading of CalciMedica

Several institutional investors have recently made changes to their positions in the company. BML Capital Management LLC increased its stake in CalciMedica by 10.3% during the first quarter. BML Capital Management LLC now owns 160,424 shares of the company’s stock worth $667,000 after acquiring an additional 15,000 shares during the last quarter. Meritage Portfolio Management grew its holdings in shares of CalciMedica by 360.0% during the 4th quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after purchasing an additional 36,000 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of CalciMedica during the 3rd quarter worth about $432,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.